Abstract
Patients with non-small cell lung cancer (NSCLC) who develop leptomeningeal metastasis (LM) have a poor prognosis. There is no standard treatment for LM with EGFRm NSCLC. Recently, EGFR tyrosine kinase inhibitors (TKIs) has been shown to be a potential therapeutic option for patients with EGFRm NSCLC and LM. Preclinical evidence shows that third-generation EGFR-TKIs, being investigated as a therapy for LM, have greater penetration of the blood-brain barrier compared with first- and second-generation treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
